Merus and Halozyme Form Partnership and Licensing Deal for Petosemtamab
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 17 2025
0mins
Should l Buy HALO?
Collaboration Announcement: Merus (MRUS) and Halozyme Therapeutics (HALO) have entered into a global non-exclusive collaboration and license agreement.
Technology Licensing: Merus has licensed Halozyme's ENHANZE drug delivery technology for the subcutaneous administration of petosemtamab, an EGFR x LGR5 bispecific antibody.
Financial Terms: The agreement includes an upfront payment from Merus to Halozyme, along with potential future milestone payments based on commercial success.
Royalty Structure: Halozyme will receive low to mid-single digit royalties on net sales of petosemtamab formulated with the ENHANZE technology during the royalty term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HALO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HALO
Wall Street analysts forecast HALO stock price to rise
5 Analyst Rating
3 Buy
1 Hold
1 Sell
Moderate Buy
Current: 63.660
Low
56.00
Averages
78.50
High
90.00
Current: 63.660
Low
56.00
Averages
78.50
High
90.00
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halozyme to Release Q1 2026 Financial Results on May 11
- Earnings Release Schedule: Halozyme Therapeutics will release its Q1 2026 financial and operating results on May 11, 2026, after market close, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 1:30 PM PT/4:30 PM ET to discuss the results, providing a convenient online registration link, which highlights its focus on investor relations.
- Technological Innovation Expansion: Halozyme's ENHANZE® drug delivery technology has impacted over one million patients across more than 100 global markets, indicating its broad application and market recognition in the biopharmaceutical sector.
- New Technology Partnerships: The collaboration with Hypercon™ and Surf Bio further expands the drug delivery technology portfolio, signaling a new standard for drug administration in home and healthcare settings, thereby enhancing market competitiveness.
See More
Halozyme Appoints New CFO Darren Snellgrove
- Executive Appointment: Halozyme Therapeutics has announced the appointment of Darren Snellgrove as Chief Financial Officer, effective June 8, 2026; Snellgrove previously led investor relations at Johnson & Johnson and brings over 30 years of industry experience, which is expected to enhance the company's financial management and strategic planning capabilities.
- Financial Strategy Leadership: As the new CFO, Snellgrove will oversee Halozyme's financial operations and strategy, including capital allocation, corporate development, and investor relations, a move that could bolster the company's performance in capital markets and investor confidence.
- Industry Background: Snellgrove's experience at Johnson & Johnson has familiarized him with the financial operations of large pharmaceutical companies, and he is expected to leverage this experience to optimize Halozyme's financial structure and drive sustained growth in the biopharmaceutical sector.
- Future Outlook: With Snellgrove's arrival, Halozyme may achieve more efficient management in financial decision-making and strategic execution, thereby laying a solid foundation for the company's long-term development.
See More
Halozyme Appoints New Chief Financial Officer
- Executive Appointment: Halozyme announced the appointment of Darren Snellgrove as Chief Financial Officer effective June 8, 2026, who will lead the company's financial operations and strategy, expected to enhance capital allocation and investor relations efficiency.
- Extensive Experience: Snellgrove brings over 30 years of financial leadership experience, having previously led investor relations at Johnson & Johnson, where he successfully reshaped corporate messaging and investor engagement strategies, strengthening analyst and shareholder relationships.
- Strategic Impact: As CFO of Johnson & Johnson's Pharmaceuticals sector, Snellgrove provided global financial leadership for a business generating over $50 billion in annual revenue, driving significant investments across commercial operations, R&D, and business development.
- Technological Innovation: Halozyme's ENHANZE® technology has been commercialized globally, improving the delivery of biologics, and Snellgrove's addition is expected to further drive sustainable growth and shareholder value creation.
See More
Halozyme and Vertex Enter Exclusive Licensing Agreement
- Exclusive Licensing Agreement: Halozyme Hypercon has entered into an exclusive licensing agreement with Vertex Pharmaceuticals, allowing Vertex to utilize Hypercon technology for the development of up to three drug targets, indicating strong interest in innovative drug delivery solutions.
- Upfront Payment and Royalties: As part of the deal, Vertex will provide Halozyme with $15 million upfront, along with royalties on net sales once products based on Hypercon technology are commercialized, which is expected to generate significant revenue for Halozyme.
- Technological Advantage: The Hypercon microparticle technology enables at-home drug administration with a lower volume but the same dosage, greatly enhancing patient convenience and aligning with current trends in drug delivery.
- Market Potential: Halozyme has previously licensed Hypercon technology to companies like Janssen and Eli Lilly, showcasing the broad applicability of this technology in the pharmaceutical industry and further solidifying Halozyme's leadership in drug delivery innovations.
See More
Halozyme Enters Exclusive Collaboration with Vertex Pharmaceuticals
- Collaboration Details: Halozyme's subsidiary Halozyme Hypercon has entered into a global exclusive collaboration with Vertex Pharmaceuticals, which will license Halozyme's Hypercon™ technology for up to three drug targets, significantly enhancing drug delivery convenience.
- Upfront Payment and Potential Earnings: Under the agreement, Vertex will make a $15 million upfront payment to Halozyme, along with potential future milestone payments, which will provide a substantial revenue stream and enhance Halozyme's financial stability.
- Technological Innovation and Market Potential: The Hypercon™ technology allows for hyperconcentration of drugs by reducing injection volume, enabling convenient at-home administration, which is expected to improve patient treatment experiences and expand market applications.
- Strategic Collaboration Outlook: This partnership not only showcases Halozyme's technological advantages in the biopharmaceutical sector but also combines with Vertex's innovative capabilities, potentially driving the development of transformative therapies for serious diseases and further solidifying both companies' leadership positions in the industry.
See More
Halozyme Appoints Interim CFO David Ramsay
- Interim CFO Appointment: Halozyme Therapeutics announced that David Ramsay will serve as interim CFO starting March 23, 2026, overseeing all financial operations to ensure continuity during the search for a permanent CFO.
- Extensive Financial Background: Ramsay previously held the CFO position from 2003 to 2009 and again from 2013 to 2015, during which time the company transitioned from a private entity to a billion-dollar public biopharmaceutical firm, highlighting his deep expertise in capital markets.
- Executive Search Underway: The company stated that the search for a permanent CFO is actively progressing, having engaged a leading executive search firm to identify candidates with a blend of capital markets expertise and strategic insight, thereby enhancing the company's financial leadership.
- Market Reaction: Following the announcement, Halozyme's stock price fell 0.88% in pre-market trading to $65.89, reflecting market caution regarding the changes in interim management.
See More
Halozyme to Release Q1 2026 Financial Results on May 11
- Earnings Release Schedule: Halozyme Therapeutics will release its Q1 2026 financial and operating results on May 11, 2026, after market close, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 1:30 PM PT/4:30 PM ET to discuss the results, providing a convenient online registration link, which highlights its focus on investor relations.
- Technological Innovation Expansion: Halozyme's ENHANZE® drug delivery technology has impacted over one million patients across more than 100 global markets, indicating its broad application and market recognition in the biopharmaceutical sector.
- New Technology Partnerships: The collaboration with Hypercon™ and Surf Bio further expands the drug delivery technology portfolio, signaling a new standard for drug administration in home and healthcare settings, thereby enhancing market competitiveness.
See More
Halozyme Appoints New CFO Darren Snellgrove
- Executive Appointment: Halozyme Therapeutics has announced the appointment of Darren Snellgrove as Chief Financial Officer, effective June 8, 2026; Snellgrove previously led investor relations at Johnson & Johnson and brings over 30 years of industry experience, which is expected to enhance the company's financial management and strategic planning capabilities.
- Financial Strategy Leadership: As the new CFO, Snellgrove will oversee Halozyme's financial operations and strategy, including capital allocation, corporate development, and investor relations, a move that could bolster the company's performance in capital markets and investor confidence.
- Industry Background: Snellgrove's experience at Johnson & Johnson has familiarized him with the financial operations of large pharmaceutical companies, and he is expected to leverage this experience to optimize Halozyme's financial structure and drive sustained growth in the biopharmaceutical sector.
- Future Outlook: With Snellgrove's arrival, Halozyme may achieve more efficient management in financial decision-making and strategic execution, thereby laying a solid foundation for the company's long-term development.
See More
Halozyme Appoints New Chief Financial Officer
- Executive Appointment: Halozyme announced the appointment of Darren Snellgrove as Chief Financial Officer effective June 8, 2026, who will lead the company's financial operations and strategy, expected to enhance capital allocation and investor relations efficiency.
- Extensive Experience: Snellgrove brings over 30 years of financial leadership experience, having previously led investor relations at Johnson & Johnson, where he successfully reshaped corporate messaging and investor engagement strategies, strengthening analyst and shareholder relationships.
- Strategic Impact: As CFO of Johnson & Johnson's Pharmaceuticals sector, Snellgrove provided global financial leadership for a business generating over $50 billion in annual revenue, driving significant investments across commercial operations, R&D, and business development.
- Technological Innovation: Halozyme's ENHANZE® technology has been commercialized globally, improving the delivery of biologics, and Snellgrove's addition is expected to further drive sustainable growth and shareholder value creation.
See More
Halozyme and Vertex Enter Exclusive Licensing Agreement
- Exclusive Licensing Agreement: Halozyme Hypercon has entered into an exclusive licensing agreement with Vertex Pharmaceuticals, allowing Vertex to utilize Hypercon technology for the development of up to three drug targets, indicating strong interest in innovative drug delivery solutions.
- Upfront Payment and Royalties: As part of the deal, Vertex will provide Halozyme with $15 million upfront, along with royalties on net sales once products based on Hypercon technology are commercialized, which is expected to generate significant revenue for Halozyme.
- Technological Advantage: The Hypercon microparticle technology enables at-home drug administration with a lower volume but the same dosage, greatly enhancing patient convenience and aligning with current trends in drug delivery.
- Market Potential: Halozyme has previously licensed Hypercon technology to companies like Janssen and Eli Lilly, showcasing the broad applicability of this technology in the pharmaceutical industry and further solidifying Halozyme's leadership in drug delivery innovations.
See More
Halozyme Enters Exclusive Collaboration with Vertex Pharmaceuticals
- Collaboration Details: Halozyme's subsidiary Halozyme Hypercon has entered into a global exclusive collaboration with Vertex Pharmaceuticals, which will license Halozyme's Hypercon™ technology for up to three drug targets, significantly enhancing drug delivery convenience.
- Upfront Payment and Potential Earnings: Under the agreement, Vertex will make a $15 million upfront payment to Halozyme, along with potential future milestone payments, which will provide a substantial revenue stream and enhance Halozyme's financial stability.
- Technological Innovation and Market Potential: The Hypercon™ technology allows for hyperconcentration of drugs by reducing injection volume, enabling convenient at-home administration, which is expected to improve patient treatment experiences and expand market applications.
- Strategic Collaboration Outlook: This partnership not only showcases Halozyme's technological advantages in the biopharmaceutical sector but also combines with Vertex's innovative capabilities, potentially driving the development of transformative therapies for serious diseases and further solidifying both companies' leadership positions in the industry.
See More
Halozyme Appoints Interim CFO David Ramsay
- Interim CFO Appointment: Halozyme Therapeutics announced that David Ramsay will serve as interim CFO starting March 23, 2026, overseeing all financial operations to ensure continuity during the search for a permanent CFO.
- Extensive Financial Background: Ramsay previously held the CFO position from 2003 to 2009 and again from 2013 to 2015, during which time the company transitioned from a private entity to a billion-dollar public biopharmaceutical firm, highlighting his deep expertise in capital markets.
- Executive Search Underway: The company stated that the search for a permanent CFO is actively progressing, having engaged a leading executive search firm to identify candidates with a blend of capital markets expertise and strategic insight, thereby enhancing the company's financial leadership.
- Market Reaction: Following the announcement, Halozyme's stock price fell 0.88% in pre-market trading to $65.89, reflecting market caution regarding the changes in interim management.
See More
